![Selwyn Ho](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: - $ al 31/07/2026
Selwyn Ho is the founder of Artemis Catalyst Ltd., founded in 2017, serving as Managing Director since 2019.
Current jobs include Chief Executive Officer at Signadori Bio SAS starting in 2026; Non-Executive Director at Immodulon Therapeutics Ltd. since 2022; Director at Peptomyc SL; Director at Satellos Bioscience, Inc. starting in 2025; and Non-Executive Director at Antennova, Inc. Former jobs include Chief Executive Officer at MediGene AG from 2022 to 2025; UK Managing Director & Country Manager at Allergan Ltd.; Vice President & Global Missions Lead-Cimzia at UCB SA from 2013 to 2015; VP, Head-Market Access & Strategic Marketing at Dermira, Inc. from 2016 to 2017; and Chief Business Officer at Connect Biopharma Holdings Ltd. Education includes undergraduate and doctorate degrees from Imperial College London and a graduate degree from The Royal College of Physicians.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 30/01/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SATELLOS BIOSCIENCE INC. | Director/Miembro de la Junta | 18/06/2025 |
Artemis Catalyst Ltd. | Fundador | 01/10/2017 |
Immodulon Therapeutics Ltd.
 Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Develops treatments for cancer | Director/Miembro de la Junta | 14/06/2022 |
Peptomyc SL
 Peptomyc SL Pharmaceuticals: MajorHealth Technology Develops cell penetrating peptides targeting the Myc oncoprotein for cancer treatment | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| MEDIGENE AG | Director Ejecutivo | 24/07/2025 |
| DERMIRA, INC. | Corporate Officer/Principal | 01/09/2017 |
| UCB | Corporate Officer/Principal | - |
Allergan Ltd.
 Allergan Ltd. Pharmaceuticals: MajorHealth Technology Provides eye care and speciality pharmaceutical products | Corporate Officer/Principal | - |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 11 |
|---|---|
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Allergan Ltd.
Allergan Ltd. Pharmaceuticals: MajorHealth Technology Provides eye care and speciality pharmaceutical products | Health Technology |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Develops treatments for cancer | Health Technology |
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products to patients living with chronic skin conditions | Health Technology |
Peptomyc SL
Peptomyc SL Pharmaceuticals: MajorHealth Technology Develops cell penetrating peptides targeting the Myc oncoprotein for cancer treatment | Health Technology |
Connect Biopharma Holdings Ltd.
 Connect Biopharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Artemis Catalyst Ltd. | |
Satellos Bioscience, Inc.
 Satellos Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company, which is focused on the identification, development and commercialization of drug candidates | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
